Gillian Fenton

Immediate Past -President and Immediate Past – Chair

GSK Vaccines

Gillian M. Fenton, Esq., CLP has been a member of LES (USA & Canada) since 1992. She has served in a variety of roles, including as member of the LES Insights Editorial Board and later Chair of the Editorial Board; as a volunteer mentor for the LES Foundation International Business Plan Competition, and as Director for Communications and Publications. Gillian is presently a member of the LES Board Executive Committee and serves on a number of other LES Board committees.

Gillian is presently Senior Counsel at GSK Vaccines, where she is the sole North American attorney for significant vaccines pipeline business development transactions (acquisitions, in-licenses, collaborations, out-licenses, and asset divestments). Gillian’s practice also includes a wide variety of collaborations and R&D funding agreements with U.S. Government entities (NIH/NIAID, BARDA and DARPA). Prior to joining GSK, Gillian was VP, Associate General Counsel & Chief Intellectual Property Counsel at Emergent BioSolutions Inc., where she founded the IP department and oversaw all IP activities in support of Emergent’s IPO and subsequent growth through M&A. Prior to joining EBS, while in-house patent counsel at Biogen Inc., Gillian led all IP activities in support of market launch of a new biotherapeutic product and secured a favorable outcome in a precedential patent interference proceeding. She also has over 12 years’ experience in private practice at Boston-based law firms.

Education: J.D. cum laude, Suffolk University Law School; B.Sc. Biochemistry, Trinity College. Admissions: MA, MD, DC. Registered U.S. Patent Attorney.